Pharmaceutical Technology
APRIL 23, 2024
The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 23, 2024
In a significant development for healthcare quality assurance in India, the National Accreditation Board for Hospitals & Healthcare Providers (NABH) has announced the implementation plan for the 2nd Edition of NABH Accreditation Standards for Allopathic Clinics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
APRIL 23, 2024
The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 23, 2024
Drugs like Ozempic are very effective at helping most people who take them lose weight. Semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro) are the most well known in the class of drugs that mimic hormones to reduce feelings of hunger.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
APRIL 23, 2024
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.
Rethinking Clinical Trials
APRIL 23, 2024
In an analysis of data from the TSOS study, younger patients and patients who were publicly insured or uninsured were among several subgroups of patients who were at significant risk of missing follow-up outcome assessments. The report was published this week in Injury. Successful studies of interventions for patients with posttraumatic stress disorder (PTSD) require engaging with injured patients in long-term follow-up.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
APRIL 23, 2024
Chronic liver disease and associated cirrhosis account for one million deaths every year
Bio Pharma Dive
APRIL 23, 2024
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.
BioPharma Reporter
APRIL 23, 2024
Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases.
Pharma Times
APRIL 23, 2024
Severe acute malnutrition is responsible for nearly half of all child deaths globally and affects 17 million children annually
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
APRIL 23, 2024
The future of Hepion’s ASCEND-NASH study was already in the balance following cost-cutting measures last December.
Fierce Pharma
APRIL 23, 2024
Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025.
Pharmaceutical Technology
APRIL 23, 2024
Tislelizumab is greenlit as a first-line treatment in combination with certain drugs in non-small cell lung cancer.
pharmaphorum
APRIL 23, 2024
Unlock the power of digital health through AI and clinical advancements. Learn how these technologies are shaping the future of healthcare and how to harness their potential.
Pharmaceutical Technology
APRIL 23, 2024
LightOx explained how light-activated drugs can be used to treat cancer on day one of the Biotrinity 2024 conference in London.
pharmaphorum
APRIL 23, 2024
After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product
Pharmaceutical Technology
APRIL 23, 2024
At the Swiss Biotech Day Conference, key opinion leaders discussed ways to reduce disparities caused by reduced regulatory capacities.
Antidote
APRIL 23, 2024
Equitable access to medical care is valuable for everyone, and an important part of this equation is health literacy. Health literacy encompasses not just access to medical care, but also the ability to understand and use medical guidance. This can include anything from a doctor’s suggestions, to medication dosage information, and aftercare guidance.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
APRIL 23, 2024
At the Swiss Biotech Day conference, key opinion leaders discussed trends in pharmaceutical partnerships.
pharmaphorum
APRIL 23, 2024
In an on-site interview at Reuters Pharma Europe in Barcelona, this week’s podcast saw Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discuss revitalising Europe’s pharmaceutical landscape and leveraging legislation for health and competitiveness.
Pharmaceutical Technology
APRIL 23, 2024
Discover Mallinckrodt Plc's innovative patent for a filter apparatus removing liquid from gas efficiently. Learn about the unique features and benefits of this groundbreaking technology.
pharmaphorum
APRIL 23, 2024
Novartis has proposed ex-BMS CEO Caforio as the successor to chair Joerg Reinhardt when he steps down next year, as it posts a strong set of Q1 results
Pharmaceutical Technology
APRIL 23, 2024
Discover MiMedx Group Inc's patented kit for medical applications, featuring modified amniotic fluid free of salts and cells. Treat various conditions with this innovative solution.
Drug Patent Watch
APRIL 23, 2024
Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate drug development and reduce costs.
Pharmaceutical Technology
APRIL 23, 2024
Unlock the potential of nucleic acid research with Takara Holdings Inc's patented method for depleting target nucleic acids. Discover how nucleic acid guided nucleases revolutionize diagnostics and research.
BioSpace
APRIL 23, 2024
This is the first round in a series of cuts that will cost 75 people their jobs this year, according to a WARN notice. Employees in other states are affected as well.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
APRIL 23, 2024
Discover Omeros Corp's groundbreaking patent for treating graft-versus-host disease post stem cell transplant with a MASP-2 inhibitory agent. Learn more about this innovative method now!
pharmaphorum
APRIL 23, 2024
Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat serious infections caused by MDR Gram-negative bacteria in adults.
Pharmaceutical Technology
APRIL 23, 2024
Discover Insmed Inc's groundbreaking patent for lipo-glycopeptide derivatives to combat bacterial infections in the lungs, including cystic fibrosis patients. Learn about the innovative method using nebulizers, DPIs, and MDIs.
Fierce Pharma
APRIL 23, 2024
As doctors and patients in the U.S. | As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
253 
Let's personalize your content